San Rocco Therapeutics Salutes The Waltons

In 1995, driven by love of their children, the Patrick Girondi and John Walton families united to fight life-threatening health conditions which afflicted their sons.

Today, after 30 years, the collaboration promises accessible gene replacement therapy for Sickle Cell and Thalassemia patients. San Rocco’s original product was the first in patients in 2012. Clinical Trials will continue in 2026 in the US and Europe.

The new San Rocco Therapeutics product, “MiNiRoLu,” named in honor of 4 patients (including the Girondi and Walton sons), was developed by a team of scientists led by Professors Frank Park, Andrew Wilber and Dr. John Tisdale, Head of Gene and Cell Therapy at the National Institutes of Health. Megan Euker helps lead the SRT team as the newly promoted Vice President of the company.